Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Santhi Reddy Ganji"'
Autor:
Robert Ardecky, Daniela G. Dengler, Kaleeckal G. Harikumar, Mathew M. Abelman, Jiwen Zou, Bryan A. Kramer, Santhi Reddy Ganji, Steve Olson, Alina Ly, Nikhil Puvvula, Chen-Ting Ma, Raghuveer Ramachandra, Eduard A. Sergienko, Laurence J. Miller
Publikováno v:
SLAS Discovery, Vol 29, Iss 6, Pp 100176- (2024)
Agonists of the secretin receptor have potential applications for diseases of the cardiovascular, gastrointestinal, and metabolic systems, yet no clinically-active non-peptidyl agonists of this receptor have yet been developed. In the current work, w
Externí odkaz:
https://doaj.org/article/3eddfc13db42404aa4f87b29244f0ab2
Autor:
Kate Welsh, Snezana Milutinovic, Robert J Ardecky, Marcos Gonzalez-Lopez, Santhi Reddy Ganji, Peter Teriete, Darren Finlay, Stefan Riedl, Shu-Ichi Matsuzawa, Clemencia Pinilla, Richard Houghten, Kristiina Vuori, John C Reed, Nicholas D P Cosford
Publikováno v:
PLoS ONE, Vol 11, Iss 9, p e0161952 (2016)
Members of the Inhibitor of APoptosis (IAP) protein family suppress apoptosis within tumor cells, particularly in the context of immune cell-mediated killing by the tumor necrosis factor (TNF) superfamily cytokines. Most IAPs are opposed endogenously
Externí odkaz:
https://doaj.org/article/586e88ab700843089041a6fb4004bf01
Autor:
Kristiina Vuori, Nicholas D.P. Cosford, John C. Reed, Kate Welsh, Curt T. Hauser, Trina R. Cooley, Ying Su, Hongbin Yuan, Santhi Reddy Ganji, Robert J. Ardecky, Marcos González-López, Mitchell Vamos, Darren Finlay
PDF - 53KB, Legend for Supplementary Figure 1.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f12185c74bb597eff8220a84448b54e
https://doi.org/10.1158/1535-7163.22503459.v1
https://doi.org/10.1158/1535-7163.22503459.v1
Autor:
Kristiina Vuori, Nicholas D.P. Cosford, John C. Reed, Kate Welsh, Curt T. Hauser, Trina R. Cooley, Ying Su, Hongbin Yuan, Santhi Reddy Ganji, Robert J. Ardecky, Marcos González-López, Mitchell Vamos, Darren Finlay
PDF - 2226KB, Cell viability assays of A) breast cancer cell lines treated with increasing concentrations of the indicated IAP antagonists, B) cancer cells isolated from a patient mammary tumor fragment pretreated with vehicle or 5 μM of the indicat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0973df3f26c30eec6ca1ebd86e91a52b
https://doi.org/10.1158/1535-7163.22503462
https://doi.org/10.1158/1535-7163.22503462